Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Medicare Drug Coverage Plans for Rheumatologic Medications

From the College  |  January 19, 2016

Different parts of Medicare cover different services. For outpatient prescription drugs, Medicare has two distinct programs with a maze of complex policies. Most physicians along with Medicare patients, retail pharmacies, Medicare drug plans as well as Medicare Advantage health plans continuously struggle with navigating Medicare drug coverage under Part B and Part D. There are…

The ACR’s Current Healthcare Policy Priorities

From the College  |  January 19, 2016

The ACR advocates on behalf of rheumatologists, rheumatology health professionals and the rheumatology community through involvement in federal and state legislation and regulatory action, participation in hearings and education of lawmakers on issues important to rheumatologists, health professionals and patients. Through robust federal and state advocacy programs, the ACR engages lawmakers and informs them of…

Rheumatology Coding Corner Questions: ICD-10 Coding Guidelines, Conventions Refresher Quiz Part 1

From the College  |  January 19, 2016

What is the ICD-10 guideline to code for osteoporosis without a current pathological fracture? There is no rule. Code for the osteoporosis, and code for the pathological fracture. Code for the osteoporosis from the M81._ category, and code for the history of a pathological fracture. None of the above is correct. How many characters are…

Rheumatology Coding Corner Answers: ICD-10 Coding Guidelines, Conventions Refresher Quiz Part 1

From the College  |  January 19, 2016

Take the challenge. C—The guideline for coding from category M81._ is that an additional code is needed if the physician has knowledge that the patent had a past pathological fracture. The code for personal history of (healed) pathological fracture is Z87.310. B—Osteoporosis with a current pathologic fracture is one of the few ICD-10 codes that…

The ACR’s Legislative Action Center Ensures Rheumatology’s Voice Is Heard in Washington

From the College  |  January 19, 2016

It’s easier than ever to become a part of advocacy efforts at the federal and state levels. Visit the ACR’s new Legislative Action Center to send a personalized message to your lawmakers, asking them to give patients access to treatments, to provide funding for biomedical research and to prevent insurer practices from interfering with treatment…

Rheumatology Research Foundation Launches Honorary Board of Advisors

From the College  |  January 19, 2016

Nearly 150 of the Rheumatology Research Foundation’s most generous supporters gathered in November during the 2015 ACR/ARHP Annual Meeting for the Donors of Merit recognition event. In celebration of the Foundation’s 30th Anniversary in 2015, the event reflected on the journey to advance treatments and improve patient care. The Foundation’s president, David Karp, MD, PhD,…

The ACR Advances Rheumatology Through Simple Tasks Campaign

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  January 19, 2016

It’s a scenario that occurs all too often. After you tell someone you’re a rheumatologist, you receive that look—the blank stare, as if you’ve spoken to them in a foreign language. Six years ago, this scenario sparked a conversation among the ACR’s leaders about the importance of promoting our profession to the public, including key…

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Simon M. Helfgott, MD  |  January 19, 2016

Every so often, a major scientific breakthrough profoundly alters the trajectory of scientific research. In the 1960s, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and…

Set Realistic Career Goals to Reach Your Professional Potential

Set Realistic Career Goals to Reach Your Professional Potential

Karen Appold  |  January 19, 2016

As a rheumatologist, you’re used to having goals. After all, you set your sights on becoming a physician, achieved the necessary educational degrees and passed required exams. After meeting your educational goals, you landed a job at an academic medical center or an established rheumatology practice, or you may have started your own practice. So…

French ‘Cannabis’ Drug Trial Leaves 1 Brain Dead, 5 Injured

Matthias Blamont  |  January 19, 2016

PARIS (Reuters)—One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in western France of an experimental medicine from an unnamed drug company, the French health ministry said on Friday, Jan. 15. The ministry did not say what the medicine was intended to be used…

  • « Previous Page
  • 1
  • …
  • 531
  • 532
  • 533
  • 534
  • 535
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences